^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Endometrial Adenocarcinoma

    Related cancers:
    2d
    CRC.0007: A clinical trial studying the effect of Tirzepatide in women living with endometrial cancer (2025-523877-40-00)
    P1/2, N=78, Not yet recruiting, University College Dublin
    New P1/2 trial
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    TP53 wild-type
    6d
    Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease (clinicaltrials.gov)
    P=N/A, N=1715, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    6d
    PRAME Immunohistochemical Expression as a Diagnostic Tool to Distinguish Between Endocervical and Endometrial Adenocarcinomas. (PubMed, Int J Gynecol Pathol)
    PRAME nuclear expression is highly sensitive and specific for carcinomas of endometrial and tubo-ovarian origin, with minimal expression in endocervical adenocarcinomas and ovarian mucinous carcinomas. PRAME IHC may be an adjunct tool to determine the site of origin in gynecologic carcinomas of uncertain primary.
    Journal • IO biomarker
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    9d
    ACR-368-201: A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma (clinicaltrials.gov)
    P2, N=72, Recruiting, Acrivon Therapeutics | N=48 --> 72
    Enrollment change
    |
    OncoSignature® Test
    |
    gemcitabine • prexasertib (ACR-368)
    13d
    ACR-368-201: A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma (2025-524542-10-00)
    P1/2, N=48, Not yet recruiting, Acrivon Therapeutics Inc.
    New P1/2 trial
    |
    gemcitabine • prexasertib (ACR-368)
    18d
    A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Florida | N=30 --> 20
    Enrollment change
    21d
    NRG-GY014: Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    ARID1A (AT-rich interaction domain 1A)
    |
    MSI-H/dMMR • ARID1A mutation
    |
    Tazverik (tazemetostat)
    22d
    Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer (clinicaltrials.gov)
    P2, N=28, Completed, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2026 --> Mar 2026 | Trial primary completion date: Aug 2026 --> Mar 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    Verzenio (abemaciclib) • fulvestrant
    25d
    ER-Negative Endometrial Cancers: An Evolving Diagnostic Category with Major Clinical Implications. (PubMed, Cancers (Basel))
    Key diagnostic clues and common pitfalls are discussed, underscoring a practical workflow in which ER negativity serves as a diagnostic signal rather than a terminal category. Improved recognition and subclassification of ER-negative endometrial carcinomas are essential for accurate diagnosis, prognostic stratification, and optimized clinical management.
    Review • Journal
    |
    ER (Estrogen receptor)
    |
    ER negative
    28d
    Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (clinicaltrials.gov)
    P2, N=32, Active, not recruiting, Sun Yat-sen University | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lenvima (lenvatinib) • Kaitanni (cadonilimab)
    29d
    NRG-GY012: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone (clinicaltrials.gov)
    P2, N=288, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Truqap (capivasertib) • Recentin (cediranib)
    29d
    Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, AstraZeneca | N=24 --> 108
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    KRAS mutation • KRAS G12D • KRAS G12